thermo fisher acquir qiagen billion
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim jan
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
bigger alway better thermo fisher nonetheless
maintain torrid pace acquisit ultim goal
becom go-to provid life scienc instrument
consum recent firm acquir affymetrix fei
patheon remain cautiou regard growth-via-acquisit
strategi yet see evid billion
compani spent acquisit sinc yield
benefit return invest capit
acquisit strategi howev allow firm
significantli broaden product offer turn allow
steadili gain market share one-stop shop approach afford
price flexibl result strong custom relationship
compani find recept audienc larg pharma client
see sizabl benefit simplifi procur process
thermo fisher offer result firm penetr pharma
expand expect continu even see
deceler biopharma spend growth torrid current
thermo fisher emerging-market presenc also impress
grow rapidli total sale firm
significantli expand manufactur footprint area
allow compet effect indigen manufactur
brand carri great power among research given
on-going commit research particularli life scienc
emerging-market govern compani goal
expand emerging-market busi annual
firm effort yield organ market share gain
core strategi remain growth acquisit
aggress clearli state capital-deploy strategi
remain risk firm could overpay yet anoth sizabl
deal fuel cheap financ said ever-expand
presenc virtual area life scienc research part
achiev acquisit afford thermo fisher opportun
capit strong secular growth expect sector
next decad
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
thermo fisher scientif sell scientif instrument laboratori
equip diagnost consum life scienc reagent firm
oper four segment analyt technolog sale
specialti diagnost product life scienc solut lab
product servic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
thermo fisher acquir qiagen billion
rumor circul late last year discuss
thermo fisher scientif note
would opportun time serial acquir like
thermo fisher pick compani midst
chang announc march agreement
two board director target
valuat stand-alon intrins valuat
anticip deal close plan
first half expect rais fair valu
estim match offer eur per share per
share current exchang rate anticip
materi chang fair valu estim narrow moat
rate thermo fisher deal cheap
price differenti roughli equival valu
synergi anticip thermo fisher deliv
specul thermo fisher plan regard
special diagnost divis sever year unlik
segment busi larg under-perform
receiv materi invest form
acquisit particular signific
diseas fit thermo fisher need although growth
especi late lacklust also
provid complementari product portfolio genet
analysi segment thermo fisher vow
bolster integr product thermo
fisher channel rather seamless million
revenu synergi appear realist
compani target million oper synergi
probabl come sale administr
expens well tax thermo fisher shrewd
lean oper record extract cost synergi
deal anticip transact
approxim neutral return invest capit
assum cost save materi
rais fair valu estim per share
due mainli cash flow realiz sinc previou
report also slightli higher forecast
includ currenc headwind revenu
organ growth expect core busi
approxim firm continu see
steadi growth biopharma spend stabl demand
academ govern custom particularli
unit state improv perform industri
end market long-term expect double-digit
growth emerg market need off-set much
matur inflationlik growth develop world
anticip modest benefit acquisit
long term forecast thermo fisher sale
increas approxim per year organ
firm like resum acquisit strategi
deleverag expect analyt instrument life
scienc segment drive futur growth matur
catalog busi provid cash flow fund
invest growth area anticip thermo fisher
adjust oper margin exclud amort
improv basi point next five year line
firm
manufactur shift lower-cost region effici
improv off-set price pressur
mani commod product
compani key end market biopharma hard
land develop world china deceler
fair valu estim fall per share thermo fisher
knack cost control challeng growth
environ also propens supplement
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
infrastructur along broad product
offer rang scientif instrument lab
equip softwar servic steadi consolid
variou busi
instrument fisher catalog phadia dionex
life affymetrix fei patheon acquisit allow
compani market one-stop shop
research custom appeal featur laboratori
look simplifi procur function addit
life patheon compani consum servic
busi even massiv account total
sale entrench custom base autom
inventori manag across broad array product
strong sell point compani compani
access custom channel unparallel legaci
next-largest competitor significantli
smaller presenc also afford firm massiv
cross-sel opportun thermo fisher salesforc
also far largest industri allow
compani penetr emerg market final
distribut network give firm unmatch scale
marketplac
thermo fisher also domin posit within
signific switch cost result costli
up-front invest equip exceed
million train instal instrument
requir recur stream consum purchas
servic revenu therebi insul thermo fisher
full brunt capit cycl competitor pressur
hesit award thermo fisher wide econom moat
larg lack confid compani abil
persist gener return invest capit
excess cost primarili owe acquisit strategi
opt includ acquisit associ goodwil
assumpt
on-going capit deploy
requir compani use acquisit
intern growth acquisit henc growth
environ remain constrain compani could opt
becom aggress acquisit front provid
addit risk share
perform industri end market also one
key variabl underli assumpt thermo
fisher expect high-single-digit organ revenu
growth firm analyt busi low-single-digit
growth laboratori segment assumpt
fairli conserv given concern
durat current bullish spend cycl hesit
incorpor aggress assumpt
mid-single-digit growth develop market china
deliv double-digit growth throughout forecast
signific upsid valuat posit scenario
valu compani per share slightli ahead
recent share price
thermo fisher narrow moat come scale
scope busi -- enorm manufactur sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
supplement intern research develop
deal size grow larger thermo fisher increasingli
face scenario deploy capit value-dilut
manner particularli interest rate increas
thermo fisher moat widen compani
low-cost posit rais
custom compani
distribut network alreadi far largest
offer scale advantag competit continu
grow rapidli particularli low-cost manufactur
area compani strong on-the-ground presenc
china coupl alreadi well-establish bond
multi-national compani expand
market allow capit market
rapid growth also cement tight relationship
custom unlik larg instrument maker
larger compani instal base stronger
competit advantag equip busi due
switch cost high-margin recur revenu stream
final increas abil offer custom
complet solut procur need allow
thermo fisher gradual muscl smaller peer
even gain ground larger organ
come wallet share particularli among main
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oth firm target market approxim billion
total sale way billion thermo
fisher largest supplier research instrument
consum
aggress acquir
compani expans strategi depend heavili
success acquisit earn number
pollut signific non-gaap adjust
othermo fisher among industri leader nearli
ubiquit research lab across globe
oth compani track record effect
excel particularli mass spectrometri
one global leader base larg home-
firm diagnost busi struggl
gener momentum legaci phadia
busi strong foothold europ overal
growth subpar
oth compani abl fuel acquisit spree via
access extrem inexpens debt gener
excess return acquisit less favor
interest rate environ might challeng
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end thermo fisher carri billion long-
short-term debt time ebitda held
billion cash balanc sheet acquisit
fei affymetrix patheon delay manag goal
achiev target leverag time within
month complet acquisit
solvenc concern limit manag state
past would will boost debt leverag
time right opportun given current
size could give enough flexibl complet deal
compar fei compani gener robust cash
flow concern regard solvenc minim
furthermor compani cash flow rather
predict consum servic account
major total sale anticip thermo fisher
remain aggress acquisit share buyback
compani pay dividend rather small rel
free cash flow
firm exposur industri end market increas
vulner prolong secular downturn fei
semiconductor busi particular could sever
affect industri spend peak cycl
current declin compani key environment
instrument target market -- china india -- reduc
environment qualiti test due fiscal concern
currenc headwind could off-set thermo
recoveri life scienc market compani face
tough competit analyt instrument busi
particularli
thermo also depend research activ academia
govern could advers affect delay
fund feder nation institut
busi signific risk technolog
nascent final acquisit strategi continu
expos firm risk overpay increasingli larger
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
acquisit inabl integr acquir busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
believ manag team perform
ultim judg success acquisit
strategi yet produc meaning return
invest capit access cheap financ fuel
recent buy spree interest see whether
chase earn per share growth backfir rate
eventu rise think manag team fare
well integr numer acquisit deploy
cash flow value-accret way success
acquisit signific challeng ceo marc
larger
compani suggest return capit metric
discuss frequent late improv
next five year howev chronic acquisit make
promis rather murki see opportun
continu drive margin improv intern
improv synergi ignor dilut
impact acquisit believ continu
return compani emphasi adjust ep
obscur realiti acquisit play role
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund growth fund amer
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
billion organ basi year year
adjust oper margin expand basi point
compani rais revenu ep
guidanc slightli forecast within updat
rang like rais fair valu estim
result time valu money believ share
overvalu current level
pharmaceut biotech channel
perform strongli double-digit revenu growth
quarter though growth moder
compani still grow faster overal industri
integr brammer track although manag
expect volatil viral vector industri
earli stage channel compani also complet
acquisit api ingredi manufactur facil
glaxosmithklin industri appli
segment growth flat high compar
basi quarter last year academ
govern divis diagnosi healthcar
divis deliv mid- high-single-digit growth rate
respect latter driven good perform
transplant diagnost immunodiagnost region
china keep grow moder pace
revenu europ north america grew
high midsingl digit respect
adjust oper margin basi point
due volum effect product gain
partial off-set product mix
thermo fisher deliv fourth quarter share
thermo fisher scientif report fourth-quart result
line expect revenu
organ basi year year adjust oper
margin roughli flat compani guidanc call
report revenu growth earn growth
forecast fall rang
maintain fair valu estim believ share
overvalu current level narrow-moat rate
pharmaceut biotech channel perform
strongli revenu growth quarter though
growth moder compani still grow
faster overal industri gain share
diagnost busi continu show progress good
growth transplant diagnost immunodiagnost
analyt segment bit fourth quarter
larg expect due tough comparison
microscopi busi deliv superb
china surprisingli light quarter low singl
digit thermo fisher blame govern decis
releas slowli capit spend fund compani
account effect right relat
coronaviru thermo fisher could potenti
adjust oper margin basi point
due volum effect product gain
partial off-set product mix
thermo fisher scientif report third-quart result
line market expect revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
